Abstract
Although type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) are two independent diseases, evidences from epidemiological, pathophysiological and animal studies have indicated a close pathophysiological relationship between these diseases. Due to the pathophysiological similarity of T2DM and AD, which includes insulin resistance and deficiency, protein aggregation, oxidative stress, inflammation, autophagocytosis and advanced glycation end products; AD is often referred to as “type 3 diabetes”. In addition to the targeted regimens usually used for treating T2DM and AD individually, currently, anti-diabetic drugs are successfully used to reduce the cognitive decline in AD patients. Therefore, if a common pathophysiology of T2DM and AD could be clearly determined, both diseases could be managed more efficiently, possibly by shared pharmacotherapy in addition to understanding the broader spectrum of preventive strategies. The aim of this review is to discuss the pathophysiological bridge between T2DM and AD to lay the foundation for the future treatment strategies in the management of both diseases.
Keywords: Type 2 diabetes mellitus, Alzheimer’s disease, pathophysiology, linkage, inflammation, oxidative stress, treatment.
Current Pharmaceutical Design
Title:Type 2 Diabetes Mellitus and Alzheimer’s Disease: Bridging the Pathophysiology and Management
Volume: 22 Issue: 28
Author(s): Fahmida Alam, Md. Asiful Islam, Teguh Haryo Sasongko and Siew Hua Gan
Affiliation:
Keywords: Type 2 diabetes mellitus, Alzheimer’s disease, pathophysiology, linkage, inflammation, oxidative stress, treatment.
Abstract: Although type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) are two independent diseases, evidences from epidemiological, pathophysiological and animal studies have indicated a close pathophysiological relationship between these diseases. Due to the pathophysiological similarity of T2DM and AD, which includes insulin resistance and deficiency, protein aggregation, oxidative stress, inflammation, autophagocytosis and advanced glycation end products; AD is often referred to as “type 3 diabetes”. In addition to the targeted regimens usually used for treating T2DM and AD individually, currently, anti-diabetic drugs are successfully used to reduce the cognitive decline in AD patients. Therefore, if a common pathophysiology of T2DM and AD could be clearly determined, both diseases could be managed more efficiently, possibly by shared pharmacotherapy in addition to understanding the broader spectrum of preventive strategies. The aim of this review is to discuss the pathophysiological bridge between T2DM and AD to lay the foundation for the future treatment strategies in the management of both diseases.
Export Options
About this article
Cite this article as:
Alam Fahmida, Islam Asiful Md., Sasongko Haryo Teguh and Gan Hua Siew, Type 2 Diabetes Mellitus and Alzheimer’s Disease: Bridging the Pathophysiology and Management, Current Pharmaceutical Design 2016; 22 (28) . https://dx.doi.org/10.2174/1381612822666160527160236
DOI https://dx.doi.org/10.2174/1381612822666160527160236 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medicinal Value and Potential Therapeutic Mechanisms of Gynostemma pentaphyllum (Thunb.) Makino and Its Derivatives: An Overview
Current Topics in Medicinal Chemistry Emerging RNA-based Drugs: siRNAs, microRNAs and Derivates
Central Nervous System Agents in Medicinal Chemistry Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology Modulation of P2 Receptors on Pancreatic β-cells by Agonists and Antagonists: A Molecular Target for Type 2 Diabetes Treatment
Current Diabetes Reviews SiO2 NPs: Promising Candidates for Drug and Gene Delivery
Drug Delivery Letters Dendrimer Based Anti-Infective and Anti-Inflammatory Drugs
Recent Patents on Anti-Infective Drug Discovery Tumor Stroma as a Target in Cancer
Current Cancer Drug Targets Topotecan and Irinotecan in the Treatment of Pediatric Solid Tumors
Current Pediatric Reviews Inhibitory Activity of Curcumin Derivatives Towards Metal-Free and Metal-Induced Amyloid-β Aggregation
Current Alzheimer Research Discovering New Treatments for Alzheimer's Disease by Repurposing Approved Medications
Current Topics in Medicinal Chemistry Nutritional and Medical Applications of Spirulina Microalgae
Mini-Reviews in Medicinal Chemistry <i>Piper sarmentosum</i> Roxb. Attenuates Beta Amyloid (Aβ)-Induced Neurotoxicity <i>Via</i> the Inhibition of Amyloidogenesis and Tau Hyperphosphorylation in SH-SY5Y Cells
Current Alzheimer Research Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors
Current Medicinal Chemistry Molecular Foundations for Personalized Therapy in Prostate Cancer
Current Drug Targets Rab5 in the Regulation of Cell Motility and Invasion
Current Protein & Peptide Science A Novel Monoclonal Antibody Against the C-terminus of β-Tubulin Recognizes Endocytic Organelles in Trypanosoma cruzi
Protein & Peptide Letters Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems
Current Medicinal Chemistry Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System
CNS & Neurological Disorders - Drug Targets Nitric Oxide and Dopamine Neurons. Implications for Parkinsons Disease
Current Medicinal Chemistry - Central Nervous System Agents